

NEWS & COMMENTARIES



Person to cherish with 438 patents

As one of the most prolific inventors, Cyprian Uzoh has recently passed an extraordinary milestone - with more than 400 U.S. patents granted with Cyprian as a named inventor. In total, Cyprian has more than 260 U.S. patents granted in his name in our portfolio alone, and a total of 401 patents in the United States and over 700 global patents to his name over his distinguished career. Born and educated in Nigeria, Cyprian studied metallurgical engineering at the University of Wisconsin - Madison and continued his graduate research in materials science at Rensselaer Polytechnic Institute, Troy, New York. His legacy is not only measured in inventions but also in mentorship and impact by advancing technology for the betterment of society.

Congratulations, Cyprian Uzoh, and thank you for your continued dedication to shaping the future of technology! <https://idiyas.com/blog/centurion-patentors-as-of-august-5-2025/2/>



FDA grants first US approval for decades-old eye drug

The FDA has approved Lenz Therapeutics' aceclidine (Vizz) for presbyopia, the loss of near vision associated with ageing. The cholinergic muscarinic receptor agonist was marketed for glaucoma in Europe as far back as 1970 (sold by Chibret as GlaucoStat), but has not previously been approved by the FDA or for the treatment of presbyopia.

<https://www.nature.com/articles/d41573-025-00138-3>



Incyte today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura® (ruxolitinib) cream 1.5%, a topical Janus kinase (JAK) inhibitor, for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not recommended.

[https://investor.incyte.com/news-](https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib)

[releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib](https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib)

SENIOR EDITOR: Dr. M. Boudjelal (KAIMRC, KSA),

CO-EDITORS Dr. M. Belhocine (AGU, Bahrain), Dr. F. Amokrane Nait Mohamed (Harvard, USA),

Dr. A. Chenna (monogram Bioscience, USA))

Follow us @ <https://www.linkedin.com/company/dz-bioscitech/>

SELECTED PUBLICATIONS

AI meets medicine: How academic–industry alliances are accelerating drug discovery

Jim Weatherall, Ph.D., Russ Altman, M.D., Ph.D.

Moderator: Erika Gebel Berg, Ph.D.

Artificial intelligence (AI) is no longer a futuristic vision in drug discovery. It's rapidly transforming every stage of the process, from uncovering disease biology to designing new molecules and optimizing clinical trials..

<https://www.science.org/content/webinar/ai-meets-medicine-how-academic-industry-alliances-are-accelerating-drug-discovery>



Lysosomes signal through the epigenome to regulate longevity across generations

Zhang et al., 2025

DOI: 10.1126/science.adn8754

The epigenome, crucial for aging, is regulated by lysosomal metabolic pathways. In *Caenorhabditis elegans*, activation of lysosomal lipid signaling and AMPK or reduction of mTOR signaling increases histone H3.3 expression, leading to life-span extension across generations. This transgenerational

prolongevity effect links the soma and germ line.


Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial

Prabhakaran et al., 2025

<https://doi.org/10.1038/s41591-025-03854-w>

A multicenter, single-blinded trial in India investigated the efficacy and safety of three commonly recommended antihypertensive dual combinations in lowering blood pressure in South Asian patients. The study randomized 1,981 Indians aged 30-79 years to a single-pill combination of amlodipine-perindopril,

perindopril-indapamide, or amlodipine-indapamide. Results showed that all three drug combinations produced similar large reductions in primary outcomes, achieving hypertension control rates in 70% of participants.




Vector-borne helminthiasis: a road map for current and future research to support control and elimination in sub-Saharan Africa

Kamgno et al., 2025

DOI: [10.1016/S1473-3099\(25\)00084-2](https://doi.org/10.1016/S1473-3099(25)00084-2)

The Commission focuses on vector-borne helminthiasis onchocerciasis, lymphatic filariasis, loiasis, and mansonellosis, endemic in sub-Saharan Africa, affecting populations in low-income countries. Onchocerciasis and filariasis are neglected tropical

diseases, while loiasis and mansonellosis are neglected and lack large-scale control programs.



GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Motso et al., 2025

DOI: [10.1016/j.cell.2025.05.042](https://doi.org/10.1016/j.cell.2025.05.042)

The study explores the balance between G proteins and β -arrestin, focusing on GPCR kinases (GRKs). Using virtual screening and chemical evolution, they developed pathway-selective β 2AR agonists that prefer GRK coupling. These compounds show lower cardiac and muscular side effects compared to standard β 2-receptor agonists and incretin mimetics, making them

promising oral alternatives for type 2 diabetes and obesity treatment.



LDL receptor promotes urinary tract infection by α -hemolysin-producing Escherichia coli and long-term histopathologic sequelae in the kidney

Possenriede et al., 2025

DOI: [10.1073/pnas.2520130122](https://doi.org/10.1073/pnas.2520130122)

Kuhn et al. studied the role of LDL receptor (LDLR) in Escherichia coli α -hemolysin entry into kidney collecting duct epithelial cells, leading to cell damage. They found that *Ldlr*^{-/-} mice had significantly lower urinary colony-forming unit (CFU) counts after

infection, spontaneous bacteriuria clearance, and renal neutrophil infiltration. The study also found that LDLR had a moderate but significant impact on long-term kidney outcome after infection.



Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial

Paton et al., 2025

DOI: [10.1016/S1473-3099\(25\)00151-3](https://doi.org/10.1016/S1473-3099(25)00151-3)

The TRUNCATE-TB trial involved 18-65-year-olds with rifampicin-susceptible pulmonary tuberculosis. Participants were randomly assigned to standard treatment or the TRUNCATE management strategy, which included initial 8-week treatment, post-treatment monitoring, and re-treatment. Four 8-week regimens were tested, with the efficacy and safety of each regimen assessed in the intention-to-treat population. The trial found that efficacy was worse with 8-week regimens, and should be used in a post-treatment monitoring and re-treatment strategy.




CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

Liu et al., 2025

<https://doi.org/10.1038/s41591-025-03783-8>

The study presents the results of a phase 1 dose escalation and dose expansion study of IBI343, an antibody-drug conjugate (ADC) targeting claudin18.2 in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. The study found that IBI343 was well tolerated, with a manageable safety profile, and promising efficacy in G/GEJ adenocarcinoma. Further research is needed to understand optimal sequencing and biomarker-informed combination therapy in G/GEJ tumors, given the development of multiple therapies targeting CLDN18.2.



Abscisic acid

NRT1.1B acts as an abscisic acid receptor in integrating compound environmental cues for plants

Ma et al., 2025

DOI: [10.1016/j.cell.2025.07.027](https://doi.org/10.1016/j.cell.2025.07.027)


Abscisic acid (ABA) is essential for how plants adjust to their environment. Current research shows that the plant's response to ABA is lower with high nitrate but increases with low nitrate, linking ABA signaling to nutritional levels. NRT1.1B is discovered to be an ABA receptor, forming a complex that initiates a response to ABA. Nitrate and ABA compete for binding to NRT1.1B, allowing plants to adapt to changing nutrient conditions.

SENIOR EDITOR: Dr. M. Boudjelal (KAIMRC, KSA),

CO-EDITORS Dr. M. Belhocine (AGU, Bahrain), Dr. F. Amokrane Nait Mohamed (Harvard, USA),

Dr. A. Chenna (monogram Bioscience, USA))

Follow us @ <https://www.linkedin.com/company/dz-bioscitech/>



Gene context drift identifies drug targets to mitigate cancer treatment resistance

Jassim et al., 2025

DOI: [10.1016/j.ccell.2025.06.005](https://doi.org/10.1016/j.ccell.2025.06.005)

The research introduces the computational pipeline REsistance through COntext DRift (RECODR), which measures changes in gene co-expression context during cancer treatment. This approach reveals important information about treatment resistance, enabling the design of effective combination treatments and the prediction of new treatments for patients with

medulloblastoma and triple-negative breast cancer.



Treg activation during allograft tolerance induction requires mitochondrion-induced TGF- β 1 in type 1 conventional dendritic cells

Schroth et al., 2025

<https://doi.org/10.1172/JCI178960>.

Conventional type 1 dendritic cells (cDC1s) are important for the tolerance of solid organ transplants, but their exact role is not fully understood. Research in mice lacking cDC1s showed these cells are necessary for tolerance induction and the survival of heart

transplants. Without cDC1s, there were fewer specific T cells that help prevent rejection. The study also found that TGF- β 1 is crucial for generating these protective T cells. Additionally, cDC1s' energy use affects their ability to support transplant tolerance.

RECOMMENDED EVENTS & JOB CORNER

KEYSTONE SYMPOSIA

Accelerating Life Science Discovery

Explore New Frontiers in Biology and Medicine

https://www.keystonesymposia.org/conferences/conference-listing?mtg_title=&mtg_type=&mtg_venue=&mtg_category=&time_range=today-forward

SENIOR EDITOR: Dr. M. Boudjelal (KAIMRC, KSA),

CO-EDITORS Dr. M. Belhocine (AGU, Bahrain), Dr. F. Amokrane Nait Mohamed (Harvard, USA),
Dr. A. Chenna (monogram Bioscience, USA))

Follow us @ <https://www.linkedin.com/company/dz-bioscitech/>

ALGERIAN SCA
 Algerian Scholars & Competencies Abroad
algeriansca-dz.org

Syngene

Putting Science to Work

- **Applications open: September 1, 2025**
- **Deadline: September 30, 2025**
- **Pitch event for finalists: October 21, 2025**

<https://www.syngeneintl.com/syngene-accelerator-award>



UK Human Functional
Genomics Initiative

Syngene Accelerator Award

Syngene is excited to launch the Syngene Accelerator Award – a unique opportunity for early-stage biotech companies to win 6 months of Integrated Drug Discovery support.

If you're an early-stage biotech company with bold science, this is your chance to accelerate your pipeline with a trusted partner.

UK Human Functional is pleased to announce several vacancies for Bioinformaticians and Research Software Engineers to join the UK Human Functional Genomics Initiative's Data Coordination Centre, based at The University of Exeter. This presents an exceptional opportunity to contribute to a UK-wide program dedicated to the development of tools and methodologies for the analysis of

functional genomic data. <https://www.ukfunctionalgenomics.com/job-vacancies/>



Recursion®

Research Scientist, Molecular Dynamics, London, England; New York, New York

Lead the application of advanced computational physics methods, to address challenging drug discovery problems and drive project success.

Keep up with the latest scientific developments,

assess new technologies for their use in internal workflows, and devise plans for their implementation.

<https://job-boards.greenhouse.io/recursionpharmaceuticals/jobs/7184787>

Kindly share the newsletter with your network.

Let us benefit other scientists.

REGISTER FOR FREE
<https://algeriansca-dz.org/events/>



Free for everyone
REGISTER THRU



ASCA WEBINARS: CALL FOR REGISTRATION

**THE FUTURE OF BIOTECHNOLOGY
MOVING EAST: INNOVATION
AND CREATIVITY MIGRATION**

Date :
15 November 2025

Time :
4:00 PM (DZ)

Moderator



MOHAMED BOUDJELAL, MBA, PhD
Director, Drug Discovery and Development
Chairman, Medical Research Core Facility and Platforms
King Abdullah International Medical Research Center
(KAIMRC), Riyadh, KSA

Meet Our Speakers



PROF. SAID DERMINE
Senior Scientist & Director
Translational Cancer Research Facility
National Center for Cancer Care & Research Clinical
Hamad Medical Corporation (HMC), Doha, Qatar
Presentation Title: "Talents acquisition"



WASFI ALAZZAM, PhD
CMC Development & Supply Chain
Digitalization | Clinical | Biologics
Downtown, Pennsylvania, USA
*Presentation Title: "Asia's Biotech Boom: Innovation,
Operational Drivers, and Investment Opportunities
in China and the Gulf"*



PROF. RAAFAT EL-GEWELY
Professor Emeritus
University of Tromsø, Norway
*Presentation Title: "Essential tools for
biotechnology to take roots in the Gulf and
Asian economies"*



TIANYI ZHANG, PhD
Business Development Director
Executive Assistant to the CEO
Corregene Biotechnology Co. Ltd
*Presentation Title: "Technology transfer and Bio-
Economy"*

About

As the world evolves, we are witnessing a significant shift in talent, knowledge, and productivity moving eastward. This trend is evident in the field of biotechnology, where the BioEconomy, originally rooted in the West, is now increasingly thriving in Asia and the Gulf region.

To delve deeper into these influences and engage in a robust discussion about the future of biotechnology, we invite you to this panel discussion with experts in:

- Biotechnology-BioEconomy | Investment strategies | Legal frameworks |
- Talent acquisition | Bio-strategy

For more information, please feel free to reach out to admin@algeriansca-dz.org